Who is eligible under the newly expanded process to submit patient input to the CADTH pan-Canadian Oncology Drug Review (pCODR) program as an individual patient or caregiver?
pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for which a drug under review is indicated. Where patient advocacy groups do exist, individual patients and caregivers are encouraged to work directly with a patient group to have their input included in the group’s submission.
Individual patients and caregivers who wish to submit input for a cancer drug review should first contact CADTH at email@example.com to confirm the absence of a relevant patient group.
Individual patients and caregivers who wish to submit patient input for a non-cancer drug review should first contact CADTH at firstname.lastname@example.org to confirm the absence of a relevant patient group.
Is registration required for an individual patient or caregiver to make a patient submission to pCODR?
Yes. Similar to patient advocacy groups, individual patients and caregivers are required to register in order to submit their input.
What type of information must an eligible individual patient or caregiver include as part of the patient input submission to pCODR?
The individual patient or caregiver is required to identify himself or herself and provide conflict of interest information, including whether any assistance was provided in preparing the submission.
The name of the individual author will not be made publicly available. CADTH will use reasonable care to prevent the disclosure of the identity of individuals or private information in publicly available documents. CADTH will remove any information that can identify individual patients and caregivers.
What are the timelines for an individual patient or caregiver to make a patient input submission?
Similar to patient advocacy group input timelines, the specific deadline for individual patient and caregiver input is posted on the CADTH website. Individual patients and caregivers will have 10 business days after pCODR receives a drug submission. However, pCODR will strive to notify registered individual patients and caregivers when confirmation of a pending drug review is received from a potential submitter (about one month in advance), so that individual patients and caregivers have as much notice as possible about a pending drug review.
Is an individual patient or caregiver eligible to provide feedback on a pCODR Expert Review Committee (pERC) Initial Recommendation?
Yes; however, only those individual patients or caregivers who provided input early in the process for use in the preparation of the guidance reports will be eligible to provide feedback on the pERC Initial Recommendation for pERC reconsideration purposes.
Where can I find more information about the process for individual patient and caregiver input?
For additional information, please see the updated Patient Engagement Guide for details about individual patient input process for pCODR.